[2]Giuliani, S. et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 ampli...
[2]Giuliani, S. et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Arch. 469, 45–50 (2016). [3]Denkert, C. et...
BRCA1/2 mutations occurred in 6.6% of patients with human epidermal growth factor receptor 2 (HER2/neu)‐positive breast cancer. However, BRCA mutation status did not affect survival outcomes in patients who had HER2/neu‐positive breast cancer....
[14] Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall ...
[16]Mouabbi JA, Raghavendra AS, Bassett RL, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. NPJ Breast Cancer (2022) 8:131. doi: 10.1038/s41523-022-00499-7 ...
[12]Li Y, Maimaitiaili A, Qu F, Li G, Shi B, Wang Y, Zhang J, He J, Fan Z, Zhang H. Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study. Am J Cancer Res. 2023 Aug 15;13(8):3571-358...
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status si......
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer Continuation of trastuzumab plus capecitabine (XH) showed a significantly improved overall response rate and time to progression compared with capecitabine... GV Minckwitz,K...
Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol....
- 《Br J Cancer》 被引量: 53发表: 2012年 Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature significantly improves progression free survival and overall survival in HER2-positive metastatic breast cancer patients previously treated with anti-HER2-based ... ...